

Systematic analysis of funding awarded for norovirus research to institutions in the United Kingdom, 1997–2010

Michael G Head¹, Joseph R Fitchett² and Rifat Atun^{3,4}

¹Research Department of Infection and Population Health, University College London, London NW3 2PF, UK

²TB Research Group, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK

³Health Management Group, Imperial College London, London SW7 2AZ, UK

⁴Harvard School of Public Health, Harvard University, Boston, MA 02115, USA

Corresponding author: Michael G. Head. Email: m.head@ucl.ac.uk

Abstract

Objectives: Norovirus infections pose great economic and disease burden to health systems around the world. This study quantifies the investments in norovirus research awarded to UK institutions over a 14-year time period.

Design: A systematic analysis of public and philanthropic infectious disease research investments awarded to UK institutions between 1997 and 2010.

Participants: None

Setting: UK institutions carrying out infectious disease research.

Main outcome measures: Total funding for infectious disease research, total funding for norovirus research, position of norovirus research along the R&D value chain.

Results: The total dataset consisted of 6165 studies with sum funding of £2.6 billion. Twelve norovirus studies were identified with a total funding of £5.1 million, 0.2% of the total dataset. Of these, eight were categorized as pre-clinical, three as intervention studies and one as implementation research. Median funding was £200,620.

Conclusions: Research funding for norovirus infections in the UK appears to be unacceptably low, given the burden of disease and disability produced by these infections. There is a clear need for new research initiatives along the R&D value chain: from pre-clinical through to implementation research, including trials to assess cost-effectiveness of infection control policies as well as clinical, public health and environmental interventions in hospitals, congregate settings and in the community.

Keywords

norovirus, research, funding, investments, UK

Introduction

Norovirus is reportedly the most common enteric pathogen and a major cause of short-term illness in the UK.¹ Although norovirus infections, which cause vomiting and diarrhoea, are short-term and mostly

self-limiting with symptoms that typically resolve within three or four days, they create much burden on the National Health System (NHS) in the UK. With a low infectious dose and short-lived immunity, faecal–oral transmission of norovirus is common. Outbreaks of norovirus infections, which can occur in almost any environment, including congregate settings such as hospital wards, cruise ships, schools and prisons, and typically occur during the winter months, are particularly difficult for healthcare services to deal with and may attract much media attention. Oysters are the vehicle for approximately 85% of norovirus (or suspected norovirus) outbreaks related to food.¹

Outbreaks in England are reported through the Hospital Outbreak Reporting Scheme and collated by Public Health England. Norovirus has been reported as being the most common enteric pathogen in the UK, with an incidence rate of 47 community cases per 1000 person-years and 2.1 general practitioner consultations per 1000 person-years,² though the annual incidence of norovirus is unpredictable. For example, there was a 39% reduction in reported norovirus outbreaks for the July 2010 to June 2011 season compared with the previous season (with a similar pattern in the laboratory reporting).¹ However, across the winter of 2012–2013, the number of reported norovirus infections increased compared to 2011–2012 figures, owing in part to a novel dominant circulating strain and an earlier start to the norovirus ‘season’.³

In the UK national media, there has been wide coverage of these outbreaks which led to closure of hospital wards in the UK.⁴ There has also been wide UK media coverage of the increased incidence of norovirus infections in the United States of America (USA).⁵ The economic burden on the NHS of norovirus infections is significant, with an estimated cost to the NHS of around £100 million each year.⁶

According to the 2010 Global Burden of Disease Study, diarrhoeal illnesses account for the fourth greatest disease burden globally (as measured in disability-adjusted life-years) across all communicable and non-communicable diseases.⁷ However, there are no global estimates specifically on the disease burden of norovirus. This is thought to be for several reasons, including the difficult detection of the virus owing to an inability for propagation in cell culture, local genetic variations that complicates the use of commonly employed detection assays, limited reporting to health officials because of the acute and short-lasting nature of the disease, and a lack of standardization of diagnostic and surveillance programmes between countries.⁸

Reports from the surveillance systems of selected countries suggest that norovirus is likely to be high burden worldwide. There are an estimated 20.9 million cases annually in the USA.⁹ In Australia, norovirus infections were considered to be responsible for almost 80% of the non-foodborne outbreaks where the pathogen could be identified.¹⁰ There are indications that the pathogens responsible for acute infectious diarrhoea can be responsible for the development of chronic gastrointestinal disorders.¹¹

We report here the research investments awarded to UK institutions on norovirus research, as part of the Research Investments in Global Health (ResIn) project.¹²

Methods

The UK research institutions have been awarded around £2.6 billion of public and charitable funds to carry out infectious disease research over the 14-year period from 1997 to 2010.¹³ For the original study, we systematically collated and analysed data on research awards from all the major funders of biomedical research, including the Medical Research Council, Wellcome Trust, Department of Health (and the National Institute of Health Research), other government departments, Bill and Melinda Gates Foundation, the European Commission and other charities that fund research. We included in our analysis all studies related to human infectious disease (including zoonoses), where the funding was awarded to a UK institution between 1997 and 2010. The final dataset contained information on 6170 studies, and these were categorized by several disease areas, themes and specific pathogens, and by type of science along the R&D value chain (pre-clinical, phase I–III trials, phase IV and intervention studies, implementation and operational research). No private sector funding was included in this analysis as the publicly available

data are very limited from these sources and were considered to be under-representative. We excluded unfunded studies. We also excluded studies where funding was awarded to a non-UK institution that had UK partners. Analysis was carried out in Microsoft Excel and Access (versions 2000 and 2007) and Stata (version 11).

Results

We identified just 12 infectious disease studies that were specifically related to norovirus research (Table 1), of which eight were categorized as pre-clinical, three as intervention studies and one as implementation research. The total funding for these 12 studies was £5.1 million (0.2% of total funding for infectious disease research in the study period), with mean funding per study of £425,188 (standard deviation £568372) and median funding of £200,620 (inter-quartile range £91362–435731). Nine studies were university-led (three by Imperial College London), one small study was led by a National Health Service Hospital Trust in England (with funding of just £684) and two were led by the Health Protection Agency (HPA, now Public Health England) and the Department for Environment, Food and Rural Affairs. The Wellcome Trust funded five studies (total investment of £2.4 million), European Commission three studies (£2.1 million), the MRC two studies (£506,871) and the Department of Health one study (£93,570). The funding source for the final study, which received £684 for a nosocomial hospital-based study, was identified as coming from the researchers undertaking the study or another local source. There is no clear temporal trend in awards (Figure 1).


By comparison, over the study period, other enteric pathogens received far greater levels of investment, such as *Salmonella* (145 studies, total investments of £55.7 million) and *Campylobacter* (87 studies, £24.1 million). Investment for rotavirus-related research was £5.8 million across 18 studies.

The US National Institutes of Health has an online searchable database that documents their research investments. We searched this Reporter database, using 'norovirus' as a keyword for studies funded between 1997 and 2013.¹⁴ The database query used this keyword to search project titles, abstracts and project terms associated with the studies. This search produced 275 awards with total investment of \$127 million (mean funding per study \$460,130, median funding \$282,151, average total annual funding \$7.4 million). All the identified studies were awarded to US-based institutions. We did not

Table 1. Funding for studies related to norovirus research (1997–2010).

Title of study	Type of research	Start year	Host institution	Funder	Adjusted funding amount
Methods for the concentration and detection of adenoviruses and noroviruses in European bathing waters with reference to the revision of the bathing water directive 76/160/EEC	Intervention/product development + roll out	2005	Cardiff University	European Commission	£1,781,618
Molecular characterisation and intervention of norovirus replication	Pre-clinical	2007	University College London	Wellcome Trust	£1,392,170
Analysis of calicivirus replication and host cell interactions	Pre-clinical	2003	University of Reading	Wellcome Trust	£496,514
Characterisation of norovirus replication complex formation	Pre-clinical	2008	Imperial College London	MRC	£374,949
Cellular and molecular factors affecting replication of Norwalk-like viruses	Pre-clinical	2003	University of Southampton	Wellcome Trust	£329,835
Cellular and molecular factors affecting replication of Norwalk-like viruses	Pre-clinical	2003	University of Glasgow	Wellcome Trust	£202,109
Development of an oral anti-norovirus therapy	Pre-clinical	2010	Imperial College London	European Commission	£199,133
Reverse genetics for Norwalk-like viruses	Pre-clinical	2000	University of Glasgow	MRC	£131,922
Measurement of norovirus inactivation	Implementation/operational research	2009	Health Protection Agency	DH	£93,571
Detection, survival and elimination of human enteric viruses in soft fruit	Intervention/product development + roll out	2003	DEFRA	European Commission	£89,155
Rational attenuation of noroviruses	Pre-clinical	2010	Imperial College London	Wellcome Trust	£10,590
Investigation of control measures to limit norovirus infections in a hospital environment	Implementation/operational research	2004	Victoria Infirmary	Own account/local funding	£684

Figure 1. Breakdown of investment in norovirus research by funder over time.



systematically categorize the quantity of each type of research that may be included along each part of the R&D value chain.

Discussion

Statement of principal findings

This study investigated norovirus research investments awarded to UK institutions between 1997 and 2010. Twelve norovirus studies were identified with a total funding of £5.1 million, 0.2% of the total dataset of all infectious disease research (6165 studies, sum funding of £2.6 billion). Of these, eight were categorized as pre-clinical, three as intervention studies and one as implementation research. Median funding was £200,620. This appears to be unacceptably low, given the burden of disease and disability of norovirus infections, and there a clear need for new research initiatives and prioritising by the funders.

Strengths and weaknesses of the study

Our analysis systematically describes infectious disease research funding awarded to UK institutions and specifically here the investments in norovirus research, and this is the first time such an analysis has been carried out in the UK. Mapping the funding landscape in this manner can allow funders and policymakers to learn how best to invest their limited resources in order to lead to optimal outputs and health outcomes both in the UK and globally. It promotes transparency and can help to reduce duplication of investments between local and international funders.

Our study has several limitations, which are discussed more fully elsewhere.¹³ These include a lack of private sector funding, which has particular

implications in areas such as vaccine development and diagnostics. Another limitation arises because it is difficult to assess associations with other areas of research that are not directly about norovirus, but which nonetheless have an impact, such as preventive measures relating to enteric diseases generally. We rely on the original data being accurate, no attempt was made to investigate any contribution of indirect and estate costs (including the introduction of full economic costing formulae in the UK), and we do not know how much money was forwarded to any collaborating partners. Creation of disease categories and allocation of studies to the categories is subjective.

Strengths and weaknesses in relation to other studies, discussing particularly any differences in results

There is no systematic analysis available globally for norovirus research, and thus we cannot undertake an international comparison. The G-FINDER¹⁵ analysis by Policy Cures collect research data on neglected diseases, but this does not include norovirus.

Meaning of the study: possible implications for clinicians or policymakers

Institutions funding infectious disease research have not explicitly prioritized norovirus-related studies. There are challenges to pre-clinical norovirus-related research due to a lack of animal models and lack of a cell culture system.⁸ Consequently, the knowledge relating to the pathogenesis of existing and emerging strains with increased virulence is limited. It appears as though the US National Institute for Health has made proportionately greater investment in norovirus than that received by UK institutions. This highlights how information on global funding of norovirus-related research is critical in order to identify funding gaps, better prioritise funding, and to help identify countries and institutions with strengths in norovirus-related research in pre-clinical work, clinical trials, intervention studies or operational research.

Unanswered questions and future research

Research investment is needed to develop new techniques for pre-clinical research and to employ recent technological advances in studies of viruses, including in gene sequencing. Furthermore, research funding is needed for intervention studies and implementation research to identify which infection control policies and clinical interventions as well as public health and environmental measures help to effectively address norovirus outbreaks. Global incidence and

prevalence data are needed to better estimate the burden of disease and disability due to norovirus so that pathogen specific burden estimates can be developed by the Global Burden of Disease studies.

Conclusions

Research funding for norovirus infections appears to be unacceptably low, given the burden of disease and disability produced by these infections. There is a clear need for new research initiatives along the R&D value chain: from pre-clinical through to implementation research, including trials to assess cost-effectiveness of infection control policies as well as clinical, public health and environmental interventions in hospitals, congregate settings and in the community. Investment is needed to develop animal models and diagnostics tests to better characterise norovirus strains and investment in surveillance to better estimate disease burden in order to better target and prioritise future research funding.

Declarations

Competing interests: RA has received research funding from the UK Medical Research Council, the UK National Institute for Health Research, UK CRC, UK EPSRC, the UK Department for International Development and the UK Department of Health. RA is a member of the UK Medical Research Council Global Health Group. RA is a co-investigator in the National Centre for Infection Prevention and Management, Imperial College. MGH works for the Infectious Disease Research Network, which has supported the original systematic analyses of investments, and is funded by the UK Department of Health. JRF has received funds from the Wellcome Trust and is a steering group member for the Infectious Disease Research Network.

Funding: None declared

Ethical approval: Not required because no patients, animals or patient identifiable data were used in this study.

Guarantor: MGH

Contributorship: MGH, JRF and RA have been involved in systematically analysing UK research investments. RA has published widely on topics such as research health financing and R&D investments. MGH wrote the article, JRF and RA contributed to the drafts and revisions. All three authors contributed to this article fully in inception, design, review of all drafts and approved the final version.

Acknowledgements: The authors would like to acknowledge the input of the Infectious Disease Research Network and all funders who provided data for this study.

Provenance: Not commissioned; peer-reviewed by John Harris

References

1. Health Protection Agency. *Gastrointestinal Infections Annual Report, 2010*. London: Health Protection Agency, 2011. See http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317131948388 (last checked 19 October 2013).
2. Tam CC, Rodrigues LC, Viviani L, et al. Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice. *Gut* 2013; 61: 69–77. See <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3230829&tool=pmcentrez&rendertype=abstract> (last checked 19 October 2013).
3. Health Protection Agency. *HPA Update on Seasonal Norovirus Activity: 15 January 2013*. London: Health Protection Agency, 2013. See <http://www.hpa.org.uk/NewsCentre/NationalPressReleases/2013PressReleases/130115HPAupdateonseasonalnorovirusactivity/> (last checked 19 October 2013).
4. BBC News. York Hospital closes wards and cancels operations due to norovirus. *BBC News*, 13 Feb 2013. See <http://www.bbc.co.uk/news/uk-england-york-north-yorkshire-21394737> (last checked 19 October 2013).
5. Mail Online. New vomit inducing norovirus bug sweeps the nation. *Mail Online*, 13 Feb 2013. See <http://www.dailymail.co.uk/news/article-2268277/New-Vomit-inducing-Norovirus-Bug-Sweeps-Nation.html> (last checked 19 October 2013).
6. Health Protection Agency. *New Guidelines for the Management of Norovirus*. London: Health Protection Agency, 2013. See <http://www.hpa.org.uk/NewsCentre/NationalPressReleases/2011PressReleases/111125norovirusguidelines/> (last checked 19 October 2013).
7. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2013; 380: 2197–223. See [http://www.thelancet.com/journals/a/article/PIIS0140-6736\(12\)61689-4/fulltext](http://www.thelancet.com/journals/a/article/PIIS0140-6736(12)61689-4/fulltext) (last checked 19 October 2013).
8. Karst SM. Pathogenesis of noroviruses, emerging RNA viruses [Molecular Diversity Preservation International]. *Viruses* 2013; 2: 748–81. See <http://www.mdpi.com/1999-4915/2/3/748> (last checked 19 October 2013).
9. Porter CK, Faix DJ, Shiao D, Espiritu J, Espinosa BJ, Riddle MS. Postinfectious gastrointestinal disorders following norovirus outbreaks. *Clin Infect Dis* 2013; 55: 915–22. See <http://www.ncbi.nlm.nih.gov/pubmed/22715178> (last checked 19 October 2013).
10. Cretikos M, Telfer B, McAnulty J. Enteric disease outbreak reporting, New South Wales, Australia, 2000 to 2005. *N S W Public Health Bull* 2013; 19: 3. See http://www.publish.csiro.au/view/journals/dsp_journal_fulltext.cfm?nid=226&f=NB07078 (last checked 19 October 2013).
11. Dupont HL. Gastrointestinal infections and the development of irritable bowel syndrome. *Curr Opin Infect Dis* 2013; 24: 503–8. See <http://www.ncbi.nlm.nih.gov/pubmed/21844806> (last checked 19 October 2013).
12. ResearchInvestments.org. See <http://www.researchinvestments.org/> (last checked 19 October 2013).
13. Head MG, Fitchett JR, Cooke MK, Wurie FB, Hayward AC, Atun R. UK investments in global infectious disease research 1997–2010: a case study.

- Lancet Infect Dis* 2013; 13: 55–64. See <http://www.ncbi.nlm.nih.gov/pubmed/23140942> (last checked 19 October 2013).
14. National Institute for Health. NIH RePORTER – *NIH Research Portfolio Online Reporting Tools Expenditures and Results*. See <http://projectreporter.nih.gov/reporter.cfm> (last checked 19 October 2013).
15. G-FINDER. *Neglected Disease Research and Development: A Five Year Review*. Sydney: G-FINDER, 2012. See <http://polycyures.org/g-finder2012.html> (last checked 19 October 2013).

Therapeutic Advances



Keep up-to-date with the latest clinical developments in your field

SAGE's *Therapeutic Advances* series of journals is a bi-monthly forum for researchers and clinicians, each title focusing on clinical developments in a specific therapeutic area.

They provide rapid, rigorously peer-reviewed publication of original research and review articles. Each journal has a prestigious editorial faculty of internationally respected opinion leaders. There are no publishing fees, and all articles are published ahead-of-print and are free to view/download via PubMed.

Many of the titles are now indexed on PubMed, and registration is ongoing for the newer titles. Most are also indexed on SCOPUS and are regularly reviewed by the Faculty of 1000 Medicine and MEDSCAPE.

More details on how to submit papers and register for free unlimited access to any of the series' titles may be found at:

www.uk.sagepub.com/tajournals



www.uk.sagepub.com/tajournals



 SAGE